Zerbaxa 1 g/0,5 g Lyophilised Powder for Solution for IV Infusion
PDF Leaflet Revision Date: 13 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of complicated infections in adults.
Dosage (summary)
1.5 g IV every 8 hours for cIAI and cUTI; 3 g IV every 8 hours for HABP/VABP.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not established as safe in pregnancy; avoid breastfeeding.
Key Drug Interactions
- Probenecid may increase tazobactam levels.
Contraindications
- Hypersensitivity to ceftolozane or tazobactam
- Severe hypersensitivity to beta-lactams.
Common side effects
- Nausea
- Headache
- Diarrhoea
- Constipation
- Pyrexia
Counselling Points
- Report any signs of allergic reactions.
- Avoid use in suspected non-susceptible infections.
- Monitor for gastrointestinal symptoms.
Serious warnings
- Risk of Clostridium difficile-associated diarrhoea
- Monitor renal function.
Important Disclaimer
The Zerbaxa 1 g/0,5 g Lyophilised Powder for Solution for IV Infusion professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
